Hidradenitis Suppurativa: A New Indication for Adalimumab

In this edition of the “Peer to Peer” audiocast series, Dr. Vincent DeLeo speaks with Dr. Jashin J. Wu about adalimumab for the treatment of hidradenitis suppurativa (HS). Dr. Wu reviews the specifics of the approval of adalimumab for HS, including dosing information. He also discusses his own treatment algorithm for managing patients with HS. Finally, Dr. Wu speculates on future targets for current biologics that already have been approved for other indications.

Questions for Dr. Jashin Wu on adalimumab for hidradenitis suppurativa? Contact the Editorial Office and we'll post the answer here.


Limelight Video

Next Article:

Recalcitrant Ulcer on the Lower Leg

Recommended for You

Expert Content

Quizzes from MD-IQ

Research Summaries from ClinicalEdge

Related Articles